WVE Stock Forecast 2025-2026
Distance to WVE Price Targets
WVE Price Momentum
10 Quality Stocks Worth Considering Now
Researching WaVe (WVE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on WVE and similar high-potential opportunities.
Latest WVE Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, WVE has a bullish consensus with a median price target of $22.00 (ranging from $14.00 to $36.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $10.22, the median forecast implies a 115.3% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joon Lee at Truist Securities, projecting a 252.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WVE Analyst Ratings
WVE Price Target Range
Latest WVE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WVE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Feb 25, 2025 | Jefferies | Roger Song | Buy | Initiates | $26.00 |
| Nov 21, 2024 | Mizuho | Salim Syed | Outperform | Maintains | $22.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Nov 12, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $36.00 |
| Nov 4, 2024 | B. Riley Securities | Madison El-Saadi | Buy | Maintains | $22.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Oct 21, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $15.00 |
| Oct 17, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Oct 17, 2024 | JP Morgan | Eric Joseph | Overweight | Maintains | $17.00 |
| Oct 16, 2024 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $22.00 |
| Oct 16, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Upgrade | $22.00 |
| Oct 16, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $22.00 |
| Oct 4, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $7.00 |
| Oct 3, 2024 | B. Riley Securities | Madison El-Saadi | Buy | Maintains | $19.00 |
| Sep 27, 2024 | JP Morgan | Eric Joseph | Overweight | Reinstates | $13.00 |
| Sep 25, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $22.00 |
| Sep 25, 2024 | Jones Trading | Catherine Novack | Buy | Maintains | $16.00 |
| Sep 19, 2024 | B. Riley Securities | Madison El-Saadi | Buy | Initiates | $11.00 |
| Sep 9, 2024 | JP Morgan | Overweight | Initiates | $10.00 |
Wave Life Sciences Ltd. (WVE) Competitors
The following stocks are similar to WaVe based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Wave Life Sciences Ltd. (WVE) Financial Data
Wave Life Sciences Ltd. has a market capitalization of $1.57B with a P/E ratio of 0.0x. The company generates $108.30M in trailing twelve-month revenue with a -89.6% profit margin.
Revenue growth is +188.2% quarter-over-quarter, while maintaining an operating margin of +27.4% and return on equity of -73.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Wave Life Sciences Ltd. (WVE) Business Model
About Wave Life Sciences Ltd.
Develops stereopure nucleic acid therapies.
Wave Life Sciences operates in the biotechnology sector, focusing on the research and development of innovative therapies that modulate RNA to treat genetic diseases. The company generates revenue through the development and commercialization of its proprietary nucleic acid therapies, which aim to offer enhanced specificity and efficacy compared to traditional treatments.
The company targets serious diseases, particularly those related to the central nervous system, and is positioned as a pioneer in genetic medicine. Wave Life Sciences collaborates with various stakeholders in the biopharmaceutical industry to address unmet medical needs and aims to deliver transformational outcomes for patients.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
287
CEO
Dr. Paul B. Bolno M.B.A., M.D.
Country
Singapore
IPO Year
2015
Website
wavelifesciences.comWave Life Sciences Ltd. (WVE) Latest News & Analysis
Wave Life Sciences Ltd. (NASDAQ: WVE) will hold its Q4 2024 Earnings Conference Call on March 4, 2025, at 8:30 AM ET, featuring key executives and analysts from major firms.
Wave Life Sciences' earnings call indicates upcoming financial results, which can impact stock prices and investor sentiment, reflecting the company's performance and strategic direction.
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
12 days agoDosing has begun in the INLIGHT trial for WVE-007 targeting obesity, with clinical data anticipated in the second half of 2025; enrollment for the initial single dose cohort is complete.
The start of dosing in the INLIGHT trial for WVE-007 signals potential progress in obesity treatment, impacting future market prospects and stock performance for involved companies.
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
19 days agoWave Life Sciences Ltd. (Nasdaq: WVE) will hold a webcast and conference call on March 4, 2025, at 8:30 a.m. ET to discuss Q4 and full-year 2024 financial results and business updates.
Wave Life Sciences' upcoming financial results and business updates could influence stock performance, investor sentiment, and future valuation based on their progress in RNA medicines.
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
1 month agoWVE-007 is a new GalNAc-siRNA targeting INHBE mRNA, aimed at promoting sustainable weight loss by preserving muscle while reducing fat.
WVE-007's innovative approach to weight loss could disrupt the weight management market, potentially leading to significant revenue growth for the company and impacting investor sentiment positively.
Wave Life Sciences Is A Buy On Pipeline Prospects
2 months agoWave Life Sciences is focusing on stereopure oligonucleotides for genetic mutations, with positive trial data. The company has $525M in cash, ensuring financial stability for 8–10 quarters.
Wave Life Sciences shows potential for growth with strong cash reserves and promising trial results, despite past challenges. Collaborations and new data could drive stock performance in the long term.
WVE-007 is a new obesity treatment targeting INHBE to promote fat burning and muscle maintenance, potentially allowing for annual or biannual dosing.
WVE-007's innovative obesity treatment could disrupt the market, attracting interest from investors in biotech and healthcare sectors, potentially leading to significant returns.
Frequently Asked Questions About WVE Stock
What is Wave Life Sciences Ltd.'s (WVE) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, Wave Life Sciences Ltd. (WVE) has a median price target of $22.00. The highest price target is $36.00 and the lowest is $14.00.
Is WVE stock a good investment in 2025?
According to current analyst ratings, WVE has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WVE stock?
Wall Street analysts predict WVE stock could reach $22.00 in the next 12 months. This represents a 115.3% increase from the current price of $10.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Wave Life Sciences Ltd.'s business model?
Wave Life Sciences operates in the biotechnology sector, focusing on the research and development of innovative therapies that modulate RNA to treat genetic diseases. The company generates revenue through the development and commercialization of its proprietary nucleic acid therapies, which aim to offer enhanced specificity and efficacy compared to traditional treatments.
What is the highest forecasted price for WVE Wave Life Sciences Ltd.?
The highest price target for WVE is $36.00 from Joon Lee at Truist Securities, which represents a 252.3% increase from the current price of $10.22.
What is the lowest forecasted price for WVE Wave Life Sciences Ltd.?
The lowest price target for WVE is $14.00 from at , which represents a 37.0% increase from the current price of $10.22.
What is the overall WVE consensus from analysts for Wave Life Sciences Ltd.?
The overall analyst consensus for WVE is bullish. Out of 15 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $22.00.
How accurate are WVE stock price projections?
Stock price projections, including those for Wave Life Sciences Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
